Investigators assessed whether intravesical BCG is necessary for patients with high-grade T1 nonmuscle-invasive bladder cancer who have unremarkable histology on the second transurethral resection.

Trial of Cretostimogene Monotherapy in BCG-Unresponsive NMIBC Accepted at the Society of Urologic Oncology (SUO) 25th Annual Meeting - IRVINE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- CG Oncology, ...

On track to report interim data in six-month evaluable patients in ADVANCED-2 trial of TARA-002 in NMIBC in 4Q 2024Expect to ...

Sam Slutsky, an analyst from LifeSci Capital, maintained the Buy rating on CG Oncology, Inc. (CGON – Research Report). The associated ...

"With the approval of ANKTIVA and the label of activating NK cells, CD4+ CD8+ T cells with memory T cells, ImmunityBio is ...

A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve ...

There are about 80,000 new cases of bladder cancer every year in the US alone. About one-third of cases are diagnosed at late ...

The accelerated approval of Trodelvy for patients with metastatic urothelial cancer has been voluntarily withdrawn.

Lower abdominal visceral fat area (VFA), older age, and prolonged surgery are independent risk factors for developing ...

Johnson & Johnson has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for BALVERSA®▼ (erdafitinib) as a monotherapy for the treatment ...

Bladder cancer is a cancer that forms in tissues of the bladder. Most bladder cancers are transitional cell carcinomas (cancer that begins in cells that normally make up the inner lining of the ...